StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck 2024 Restructuring Program by Year

2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)

Merck 2024 Restructuring Program: $539M in FY2025, down 39.3% from a year earlier.

Latest, FY2025
539
Period ended Dec 31, 2025
Change on a year earlier
-39.3%
888 in FY2024
History
3 years
Since FY2023
Sources
1
Form 10-K (filed 2026-02-24)

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Restructuring Footnote.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)Year on yearSource
FY2025Dec 31, 2025539-39.3%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 2024888+367.4%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023190–Form 10-K (filed 2026-02-24) ↗

Breakdown

What makes up 2024 Restructuring Program

Cite this data

StockData. (2026). Merck 2024 Restructuring Program ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr-program2024-incurred

See every metric in the Merck KPI table. Data updated Oct 26, 2026.